OMICS Group International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over 400 leading-edge peer reviewed Open Access Journals and organizes over 300 International Conferences annually all over the world. OMICS Publishing Group journals have over 3 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 30000 eminent personalities that ensure a rapid, quality and quick review process. OMICS Group signed an agreement with more than 1000 International Societies to make healthcare information Open Access.
OMICS Journals are welcoming Submissions

OMICS Group welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way. OMICS Journals are poised in excellence by publishing high quality research. OMICS Group follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions.

The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website: http://omicsonline.org/Submitmanuscript.php
• **NAME:** Jun Yang, Prof. MD, PhD, doctoral supervisor

• **Gender:** Male

• **Birth Date:** April 11th, 1972

• Department of Pathology, The Second Affiliated Hospital, Xi'an Jiaotong University
  No. 157#, The West 5th Road Xi'an, Shaanxi, China 710004

• **Email:** [yangjundr@163.com](mailto:yangjundr@163.com)

• **QQ:** 1583309590

Main fields:

- Histopathology of digestive system and female genital and breast tumors
- Histopathology and pathogenesis of Hirschsprung's disease and hirschsprung'sallied disease
- Cytopathology and cytological technology
- Tumor immunity and biological immunotherapy
- Screening and identification of molecular targets of carcinoma, and using new technology for early diagnosis in carcinoma
- Detecting tumor-associated molecular targets for individualized treatment of cancers.
- Researching in biotechnology and translational medicine
The research results and clinical outcomes have been presented at conferences


The research results and clinical outcomes have been presented at conferences


Tab.1 The histological typing, grading-scale system of colorectal cancer (score)

<table>
<thead>
<tr>
<th>Tumors</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>colorectal cancer (CRC)</td>
<td></td>
</tr>
<tr>
<td>no mucin-producing adenocarcinoma</td>
<td>1-3 points</td>
</tr>
<tr>
<td>tubular adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>well differentiated tubular adenocarcinoma</td>
<td>1 point</td>
</tr>
<tr>
<td>moderately differentiated tubular adenocarcinoma</td>
<td>2 points</td>
</tr>
<tr>
<td>poorly differentiated tubular adenocarcinoma</td>
<td>3 points</td>
</tr>
<tr>
<td>sieve-like acne adenocarcinoma</td>
<td>2 points</td>
</tr>
<tr>
<td>medullary carcinoma</td>
<td>2 points</td>
</tr>
<tr>
<td>serrated adenocarcinoma</td>
<td>2 points</td>
</tr>
<tr>
<td>micropapillary carcinoma</td>
<td>3 points</td>
</tr>
<tr>
<td>mucin-producing adenocarcinoma</td>
<td>3-4 points</td>
</tr>
<tr>
<td>mucinous adenocarcinoma</td>
<td>3 points</td>
</tr>
<tr>
<td>signet ring cell carcinoma</td>
<td>4 points</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>1-3 points</td>
</tr>
<tr>
<td>well differentiated squamous cell carcinoma</td>
<td>1 point</td>
</tr>
<tr>
<td>moderately differentiated squamous cell carcinoma</td>
<td>2 points</td>
</tr>
<tr>
<td>poorly differentiated squamous cell carcinoma</td>
<td>3 points</td>
</tr>
<tr>
<td>neuroendocrine tumors</td>
<td>1-4 points</td>
</tr>
<tr>
<td>neuroendocrine tumors (NET)</td>
<td>1-4 points</td>
</tr>
<tr>
<td>NET G1</td>
<td>1 point</td>
</tr>
<tr>
<td>NET G2</td>
<td>1 point</td>
</tr>
<tr>
<td>neuroendocrine carcinoma (NEC)</td>
<td>3-4 points</td>
</tr>
<tr>
<td>small cell NEC</td>
<td>3 points</td>
</tr>
<tr>
<td>large cell NEC</td>
<td>4 points</td>
</tr>
<tr>
<td>mixed adenocarcinoma-neuroendocrine carcinoma</td>
<td>(the score was accumulated)</td>
</tr>
<tr>
<td>the special type of CRC</td>
<td>4 points</td>
</tr>
<tr>
<td>adenosquamous carcinoma</td>
<td>(the score were accumulated)</td>
</tr>
<tr>
<td>clear cell carcinoma</td>
<td>4 points</td>
</tr>
<tr>
<td>pindle cell carcinoma</td>
<td>4 points</td>
</tr>
<tr>
<td>Undifferentiated carcinoma</td>
<td>5 points</td>
</tr>
</tbody>
</table>

present interest

- Histopathology and pathogenesis of Hirschsprung's disease and hirschsprung's allied disease

Cytopathology and Cytological technology

diagnostic cytopathology of the cervical cytology and pleural effusion.

enriching of cells,

making cytological cell blocks, DNA image analysis, detecting circulating tumor cells,

using staining techniques, and ICH or FISH of cytological samples.

detecting Her-2 in cytological samples by ICH.

Automatic DNA quantitative analysis technology
/Automatic DNA image cytometry
present interest

• Tumor immunity and biological immunotherapy
Screening and identification of molecular targets of carcinoma interesting in biomarker discovery technology to screen tumor-associated Biomarker and using new technology for early diagnosis in carcinoma.

Fig. Schematic diagram of using cancer Cancer antigenomics for screening TAA
Detecting tumor-associated molecular targets for individualized treatment of cancers. using IHH, RT-PCR, FISH and sequencing analysis to provide guideline to aid individualized decision-making in the clinical management of cancers.
Research in biotechnology and Translational medicine for diagnostic cytopathology and histopathology,

Figure. Working flow of the HT-1 tissue microarrayer, and TMAs recipient paraffin block and TMAs paraffin block and TMAs sections.

Journal of Clinical & Experimental Pathology

- Journal of Neuroinfectious Diseases
- Journal of the Pancreas
- Immunome Research
- Journal of Osteoporosis and Physical Activity
- Journal of Plant Pathology & Microbiology
Clinical & Experimental Pathology Related Conferences

- International Conference on Clinical Trials- July 27-29, 2015 Florida, USA
OMICS publishing Group Open Access Membership enables academic and research institutions, funders and corporations to actively encourage open access in scholarly communication and the dissemination of research published by their authors. For more details and benefits, click on the link below:
http://omicsonline.org/membership.php